BioCentury
ARTICLE | Clinical News

Adocia begins head-to-head trial of BioChaperone Lispro vs. Fiasp and Novolog

July 28, 2017 6:12 AM UTC

In early June, Adocia S.A. (Euronext:ADOC) began a 3-way crossover Phase II trial to compare single subcutaneous doses of 0.15 U/kg BioChaperone Lispro vs. 0.15 U/kg Fiasp (faster-acting insulin aspart, NN1218) or 0.15 U/kg Novolog insulin aspart (NovoRapid) delivered under a euglycemic clamp procedure in 42 Type I diabetics.

The primary endpoint of the double-blind, German trial will evaluate the area under the curve (AUC) for glucose infusion rate (GIR) from 0 to 60 minutes. Secondary endpoints include other pharmacokinetic measures and safety. Top-line data are expected by year end...